A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

被引：4
|
作者：
Miller, D. S.
Blessing, J. A.
Krasner, C. N.
Mannel, R. J.
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Oklahoma, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5524
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study
    Duska, Linda R.
    Blessing, John A.
    Rotmensch, Jacob
    Mannel, Robert S.
    Hanjani, Parviz
    Rose, Peter G.
    Dizon, Don S.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 44 - 48
  • [42] A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
    Vergote, Ignace
    Calvert, Hilary
    Kania, Marek
    Kaiser, Christopher
    Zimmermann, Annamaria Hayden
    Sehouli, Jalid
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1415 - 1423
  • [43] A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Gold, Michael A.
    Brady, William E.
    Lankes, Heather A.
    Rose, Peter G.
    Kelley, Joseph L.
    De Geest, Koen
    Crispens, Marta A.
    Resnick, Kimberly E.
    Howell, Stephen B.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 635 - 639
  • [44] Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group
    Miller, David Scott
    Blessing, John A.
    Ramondetta, Lois M.
    Pham, Huyen Q.
    Tewari, Krishnansu S.
    Landrum, Lisa M.
    Brown, Jubilee
    Mannel, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2744 - +
  • [45] A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
    Chan, John K.
    Brady, William
    Monk, Bradley J.
    Brown, Jubilee
    Shahin, Mark S.
    Rose, Peter G.
    Kim, Jae-Hoon
    Secord, Angeles Alvarez
    Walker, Joan L.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 247 - 252
  • [46] A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study (vol 116, pg 332, 2010)
    Rocereto, Thomas F.
    Brady, William E.
    Shahin, Mark S.
    Hoffman, James S.
    Small, Laurie
    Rotmensch, Jacob
    Mannel, Robert S.
    GYNECOLOGIC ONCOLOGY, 2010, 118 (02) : 208 - 208
  • [47] A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study
    Leslie, Kimberly K.
    Sill, Michael W.
    Fischer, Edgar
    Darcy, Kathleen M.
    Mannel, Robert S.
    Tewari, Krishnansu S.
    Hanjani, Parviz
    Wilken, Jason A.
    Baron, Andre T.
    Godwin, Andrew K.
    Schilder, Russell J.
    Singh, Meenakshi
    Maihle, Nita J.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (03) : 486 - 494
  • [48] A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
    Campos, Susana M.
    Brady, William E.
    Moxley, Katherine M.
    O'Cearbhaill, Roisin E.
    Lee, Paula S.
    DiSilvestro, Paul A.
    Rotmensch, Jacob
    Rose, Peter G.
    Thaker, Premal H.
    O'Malley, David M.
    Hanjani, Parviz
    Zuna, Rosemary E.
    Hensley, Martee L.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 537 - 541
  • [49] A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Lankes, Heather A.
    Fader, Amanda Nickles
    Finkler, Neil J.
    Hoffman, James S.
    Rose, Peter G.
    Sutton, Gregory P.
    Drescher, Charles W.
    McMeekin, D. Scott
    Hu, Wei
    Deavers, Michael
    Godwin, Andrew K.
    Alpaugh, R. Katherine
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 538 - 543
  • [50] A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial
    Schilder, Russell J.
    Blessing, John A.
    Shahin, Mark S.
    Miller, David S.
    Tewari, Krishnansu Sujata
    Muller, Carolyn Y.
    Warshal, David P.
    McMeekin, Scott
    Rotmensch, Jacob
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) : 1137 - 1141
12345